



## Rapid communication

# NF279: a novel potent and selective antagonist of P2X receptor-mediated responses

Susanne Damer <sup>a</sup>, Beate Niebel <sup>a</sup>, Sittah Czeche <sup>a</sup>, Peter Nickel <sup>b</sup>, Ursula Ardanuy <sup>b</sup>, Günther Schmalzing <sup>a</sup>, Jürgen Rettinger <sup>a</sup>, Ernst Mutschler <sup>a</sup>, Günter Lambrecht <sup>a,\*</sup>

Received 16 April 1998; accepted 17 April 1998

#### **Abstract**

8,8'-(Carbonylbis(imino-4,1-phenylenecarbonylimino-4,1-phenylenecarbonylimino))bis(1,3,5-naphthalenetrisulfonic acid) (NF279) antagonized P2X receptor-mediated contractions in rat vas deferens, evoked by  $\alpha$ , $\beta$ -methylene ATP (10  $\mu$ M;  $pIC_{50} = 5.71$ ) without affecting responses mediated via  $\alpha_{1A}$ -adrenoceptors, adenosine  $A_1$  and  $A_{2B}$  receptors, histamine  $H_1$ , muscarinic  $M_3$  and nicotinic receptors. The low inhibitory potency of NF279 on P2Y receptors in guinea-pig taenia coli ( $pA_2 = 4.10$ ) and at ecto-nucleotidases in folliculated *Xenopus laevis* oocytes (IC<sub>50</sub> > 100  $\mu$ M) indicates that NF279 is a novel specific and selective P2X receptor antagonist. © 1998 Elsevier Science B.V. All rights reserved.

Keywords: P2 receptor antagonist; Suramin; NF279 (8,8'-(Carbonylbis(imino-4,1-phenylenecarbonylimino-4,1-phenylenecarbonylimino))bis(1,3,5-naph-thalenetrisulfonic acid))

P2 receptor subtypes for extracellular nucleotides comprise an ionotropic (P2X, seven subunits known) and a metabotropic (P2Y, at least four subtypes known) family (Lambrecht, 1996; Bhagwat and Williams, 1997). The characterization of native and recombinant P2 receptors continues to be hindered by the lack of specific and subtype-selective antagonists. However, a number of compounds including suramin and its truncated analogue 8,8'-(carbonylbis(imino-3,1-phenylenecarbonylimino)bis(1,3,5naphthalenetrisulfonic acid) (NF023), do exhibit selective P2 receptor subtype-blocking properties, and if used circumspectly, are of use in this respect (Humphrey et al., 1995; Bültmann et al., 1996; Lambrecht, 1996; Bhagwat and Williams, 1997). The present study was designed to evaluate the functional antagonistic properties of the novel suramin-related compound 8,8'-(carbonylbis(imino-4,1-phenylenecarbonylimino-4,1-phenylenecarbonylimino)) bis(1,3,5-naphthalenetrisulfonic acid) (NF279) on P2X receptors in rat vas deferens, P2Y receptors in guinea-pig

taenia coli and ATP breakdown by ecto-nucleotidases in folliculated *Xenopus laevis* oocytes.

Prostatic segments of vasa deferentia from rats were incubated in Krebs solution as were strips of guinea-pig taenia coli (Khakh et al., 1995; Bültmann et al., 1996). Mechanical activity was recorded isometrically, and for evaluation of concentration-response relationships, a logistic function was fitted to the data using non-linear regression analysis (Jenkinson et al., 1995; Bültmann et al., 1996). p $A_2$  values were calculated according to the Schild equation (Jenkinson et al., 1995). Ecto-nucleotidases activity of *Xenopus* oocytes was studied by measuring spectrophotometrically the production of inorganic phosphate ( $P_i$ ) from the breakdown of extracellular ATP (Ziganshin et al., 1995, Ziganshin et al., 1996). The results are presented as means  $\pm$  S.E.M. from n observations.

The three antagonists employed in the present study had no effect on the basal tone of the preparations used, and their inhibitory effect at P2 receptors was reversed on repeated wash out (up to 90 min; data not shown).

In the vas deferens, suramin, NF023 and NF279 (60–120 min exposure) concentration-dependently inhibited the contractions to single doses of  $\alpha$ ,  $\beta$ -methylene ATP (10

<sup>&</sup>lt;sup>a</sup> Department of Pharmacology, Biocentre Niederursel, University of Frankfurt, Marie-Curie-Str. 9, D-60439 Frankfurt / M., Germany
<sup>b</sup> Department of Pharmaceutical Chemistry, University of Bonn, D-53121 Bonn, Germany

<sup>\*</sup> Corresponding author. Tel.: +49-69-79829366; fax: +49-69-79829374; e-mail: lambrecht@em.uni-frankfurt.de




Fig. 1. Effect of NF279, NF023 and suramin on contractions of rat vas deferens elicited by single doses of  $\alpha, \beta$ -methylene ATP (10  $\mu$ M) mediated via P2X receptors. NF279 ( $\blacktriangledown$ , 0.3–5  $\mu$ M), NF023 ( $\spadesuit$ , 3–100  $\mu$ M) or suramin ( $\blacksquare$ , 5–100  $\mu$ M) were incubated for 60–120 min.  $\alpha, \beta$ -Methylene ATP was added at 30-min intervals. Each point represents the arithmetic mean derived from two to four experiments, vertical bars show S.E.M. where it exceeded the size of the symbol.

 $\mu$ M; tension generated in control experiments = 1499.7  $\pm$  74.8 mg; n=15) (Fig. 1). NF279 was considerably (up to 11-fold) more potent (pIC<sub>50</sub> = 5.71  $\pm$  0.01) as an P2X receptor antagonist than either NF023 (pIC<sub>50</sub> = 4.92  $\pm$  0.02) or suramin (pIC<sub>50</sub> = 4.67  $\pm$  0.03; n=2-5). NF279 (10 nM-3  $\mu$ M) also was a highly potent antagonist (pIC<sub>50</sub> = 7.26  $\pm$  0.02, n=5-9) in studies with the cloned P2X<sub>1</sub> receptor expressed in *Xenopus* oocytes, inhibiting ATP (1  $\mu$ M)-induced inward currents (two-electrode voltage-clamp recordings).

In the guinea-pig taenia coli precontracted by carbachol  $(0.1-0.3~\mu\text{M})$ , suramin  $(100~\mu\text{M},~p\,A_2=4.47\pm0.05)$ , NF023  $(300~\mu\text{M},~p\,A_2=4.05\pm0.14)$  and NF279  $(100~\mu\text{M},~p\,A_2=4.10\pm0.29;~n=3-4)$  antagonized relaxant responses to adenosine 5'-O-(2-thiodiphosphate) (EC $_{50}=0.63\pm0.09~\mu\text{M},~n=12)$  in a parallel and surmountable manner (60-min exposure), without affecting the carbachol-induced contractions. The resulting p $_{40}$  values for NF023 and NF279 were very similar, these two compounds being approximately 3- to 4-fold less potent than suramin.

Generation of  $P_i$  by ecto-nucleotidases in oocytes, using ATP (100  $\mu$ M; 4.54  $\pm$  0.20 nmol  $P_i/30$  min per cell, produced in control incubations; n=16) as substrate, was inhibited with similar potency by suramin (300  $\mu$ M, 41.2  $\pm$  1.8%), NF023 (300  $\mu$ M, 31.1  $\pm$  2.2%) and NF279 (300  $\mu$ M, 68.5  $\pm$  2.6%; n=7-31).

NF279 (100  $\mu$ M) had no significant effects on either the potency or maximum response to noradrenaline ( $\alpha_{1A}$ -adrenoceptors) in rat vas deferens, 2-chloro-N<sup>6</sup>-cyclopen-

tyladenosine (adenosine  $A_1$  receptors), histamine ( $H_1$  receptors), arecaidine propargyl ester (muscarinic  $M_3$  receptors) in guinea-pig ileum and 2-chloroadenosine (adenosine  $A_{2B}$  receptors) as well as nicotine (neuronal nicotinic receptors) in guinea-pig taenia coli, respectively (data not shown). Thus, the antagonism of NF279 appears to be specific for P2 receptors.

In conclusion, NF279 is a novel and highly potent antagonist blocking P2X receptor-mediated responses and, to the best of our knowledge, the compound with the highest P2X- versus P2Y- and ecto-nucleotidases-selectivity presently available. If used at concentrations lower than 30  $\mu$ M, effective blockade of P2X receptors by NF279 may be achieved, with little or no inhibition of P2Y receptors or ecto-nucleotidases. However, further experiments are needed to clarify its exact mechanism of actions at the known P2X and P2Y receptor subtypes.

### Acknowledgements

The authors gratefully acknowledge the financial support of the Fonds der Chemischen Industrie (Germany) and of the Deutsche Forschungsgemeinschaft (grant number La 350/7-1).

#### References

Bhagwat, S.S., Williams, M., 1997. P2 purine and pyrimidine receptors: emerging superfamilies of G-protein-coupled and ligand-gated ion channel receptors. Eur. J. Med. Chem. 32, 183–193.

Bültmann, R., Wittenburg, H., Pause, B., Kurz, G., Nickel, P., Starke, K., 1996. P<sub>2</sub>-purinoceptor antagonists: III. Blockade of P<sub>2</sub>-purinoceptor subtypes and ecto-nucleotidases by compounds related to suramin. Naunyn-Schmiedeberg's Arch. Pharmacol. 354, 498–504.

Humphrey, P.P.A., Buell, G., Kennedy, I., Khakh, B.S., Michel, A.D., Surprenant, A., Trezise, D.J., 1995. New insights on P<sub>2x</sub> purinoceptors. Naunyn-Schmiedeberg's Arch. Pharmacol. 352, 585–596.

Jenkinson, D.H., Barnard, E.A., Hoyer, D., Humphrey, P.P.A., Leff, P., Shankley, N.P., 1995. International union of pharmacology committee on receptor nomenclature and drug classification: IX. Recommendations on terms and symbols in quantitative pharmacology. Pharmacol. Rev. 47, 255–266.

Khakh, B.S., Surprenant, A., Humphrey, P.P.A., 1995. A study on  $P_{2X}$  purinoceptors mediating the electrophysiological and contractile effects of purine nucleotides in rat vas deferens. Br. J. Pharmacol. 115, 177–185.

Lambrecht, G., 1996. Design and pharmacology of selective P<sub>2</sub>-purinoceptor antagonists. J. Auton. Pharmacol. 16, 341–344.

Ziganshin, A.U., Ziganshina, L.E., King, B.F., Burnstock, G., 1995. Characteristics of ecto-ATPase of *Xenopus* oocytes and the inhibitory actions of suramin on ATP breakdown. Pflug. Arch. Eur. J. Physiol. 429, 412–418.

Ziganshin, A.U., Ziganshina, L.E., King, B.F., Pintor, J., Burnstock, G., 1996. Effects of P2-purinoceptor antagonists on degradation of adenine nucleotides by ecto-nucleotidases in folliculated oocytes of *Xenopus laevis*. Biochem. Pharmacol. 51, 897–901.